News & Updates
Filter by Specialty:
Adding canakinumab to SoC confers no survival benefit in advanced NSCLC
The addition of the monoclonal anti-interleukin-1β antibody canakinumab to the standard of care (SoC) regimen of platinum doublet chemotherapy and pembrolizumab in the first-line setting did not improve progression-free survival (PFS) or overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC), results of the phase III CANOPY-1 trial showed.
Adding canakinumab to SoC confers no survival benefit in advanced NSCLC
10 May 2022
Trabectedin–durvalumab combo shows antitumour activity in refractory ovarian carcinoma
Combination treatment with trabectedin and durvalumab appears to be promising in the treatment of patients with platinum-refractory ovarian carcinoma, shrinking tumour while having a manageable side effect profile, according to data from the phase Ib TRAMUNE trial.
Trabectedin–durvalumab combo shows antitumour activity in refractory ovarian carcinoma
10 May 2022
New chemo-free triplet regimen shows promise for endometrial cancer
A triplet regimen combining the PARP inhibitor olaparib with metronomic cyclophosphamide and metformin showed favourable signals for heavily pretreated women with advanced endometrial carcinoma, the phase I/II ENDOLA study suggests.
New chemo-free triplet regimen shows promise for endometrial cancer
09 May 2022
First-line camrelizumab-chemo combo boosts OS in advanced squamous NSCLC
Treatment comprising camrelizumab, carboplatin, and paclitaxel in the first-line setting improved overall survival (OS) in patients with advanced squamous non-small-cell lung cancer (NSCLC), according to updated results of the phase III CameL-sq trial from China.
